Use of a digital health solution after percutaneous coronary intervention: a randomised controlled trial - Summary - MDSpire

Evaluation of a Digital Health Intervention Following Percutaneous Coronary Intervention: Results from a Randomized Controlled Study

  • By

  • Elias Freyr Gudmundsson

  • Bartosz Dobies

  • Brynja Laxdal

  • Inga Valborg Olafsdottir

  • Ingibjörg Davidsdottir

  • Heida Birna Bragadottir

  • Svala Sigurdardottir

  • Ari Pall Isberg

  • Andrew Grannell

  • Berglind Libungan

  • Brynjolfur A. Mogensen

  • Hulda Halldorsdottir

  • Maria V. Gudmundsdottir

  • Bylgja Kaernested

  • Tryggvi Thorgeirsson

  • Saemundur Jon Oddsson

  • David O. Arnar

  • July 21, 2026

Share

Objective:

To evaluate a multimodal digital health intervention (SK-121) as an adjunct to standard of care (SoC) to reduce the risk of recurrent cardiovascular events in patients following percutaneous coronary intervention (PCI).

Approach:
  • Study Design: Single-centre, randomised controlled trial involving 200 patients who underwent PCI, randomised 1:1 to receive SoC alone or SoC plus a 48-week gamified digital program.
  • Intervention: The digital program focused on lifestyle modification and remote patient monitoring (RPM), with high user retention and engagement.
Key Findings:
  • No significant difference in SMART2 risk scores between intervention and control groups at 6 months (adjusted mean difference −0.3%; P = 0.821).
  • Significant improvement in disease knowledge at 6 and 12 months (P < 0.001) and medication adherence at 6 months (P = 0.030) in the intervention group.
  • Diastolic blood pressure was significantly lower in the intervention group at 12 months (−3.7 mmHg; P = 0.003).
  • In overweight participants, the intervention significantly reduced SMART2 scores at 12 months compared to controls (−3.7%; P = 0.033).
Interpretation:

The intervention did not reduce the SMART2 risk score in the overall population but improved disease knowledge, medication adherence, and diastolic blood pressure.

Limitations:
  • Single-centre study may limit generalizability.
  • Blinding was not feasible due to the nature of the intervention.
Conclusion:

The program was well-accepted and may offer prognostic benefits for overweight patients.

Sources:

Original Source(s)

Related Content